Athernal Bio is a seed startup. 1 investor tracked.
Athernal Bio is a startup founded in 2021 based in the United Kingdom. Its most recent tracked round is Seed. Brouky records 1 investor associated with the company.
Athernal Bio is developing targeted immunotherapies to treat high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia (AML) and other haematological cancers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.